Skip to main content

Gonorrhea Develops Rapid Resistance to Azithromycin


March 15, 2012 — An azithromycin-resistant variant of gonorrhea that developed in just 12 days was detected with genotyping and highlights the rapid emergence of clinical gonococcal resistance, according to a new report.
Olusegun Soge, PhD, from the Neisseria Reference Laboratory at the University of Washington, in Seattle, reported the findings at the 2012 National STD Prevention Conference, held in Minneapolis, Minnesota.
According to Dr. Soge and colleagues, the US Centers for Disease Control and Prevention (CDC) recommends dual therapy with ceftriaxone and azithromycin for the treatment of gonorrhea.
"Although azithromycin has been effective for the treatment of gonorrhea, azithromycin monotherapy is not recommended because of concerns about rapid emergence of macrolide resistance," the authors write.
The report describes the development of resistance to azithromycin in a 26-year-old man with gonococcal urethritis confirmed by culture. The patient received oral azithromycin 2 g but showed persistent symptoms suggestive of treatment failure at follow-up.
The researchers conducted antimicrobial susceptibility testing of pre- and posttreatment isolates using an agar dilution method, according to the Gonococcal Isolate Surveillance Project protocol. Molecular typing was done with Neisseria gonorrhoeae multiantigen sequence typing (NG-MAST) and pulsed-field gel electrophoresis (PFGE).
The 2 isolates had the same NG-MAST results and were indistinguishable with PFGE. They had similar susceptibility patterns, except that the minimum inhibitory concentration for azithromycin increased from 0.5 µg/mL in the pretreatment isolate to 8 µg/mL in the posttreatment isolate.
"Although spontaneous mutants of macrolide-resistant N gonorrhoeae have been successfully selected in the laboratory with in vitro studies, it was intriguing to see the selection of increased azithromycin resistance develop in a patient during treatment with 2 g of azithromycin within 12 days," Dr. Soge told Medscape Medical News.
According to Dr. Soge, this report highlights the utility of antimicrobial susceptibility testing, NG-MAST, and PFGE for investigating treatment failures.
"The emergence and spread of multidrug resistant strains of N gonorrhoeae capable of causing treatment failures could severely jeopardize gonorrhea control efforts," he added.
According to Dr. Soge, clinicians should treat gonorrhea with the CDC-recommended antibiotics: injectable ceftriaxone and either azithromycin or doxycycline.
"It is critical that healthcare providers ask patients treated with azithromycin monotherapy to return within 1 week for a test of cure," he said. "The routine use of azithromycin monotherapy for gonorrhea should be discouraged since, as we saw in this case, azithromycin treatment by itself can rapidly select resistance."
The researchers have disclosed no relevant financial relationships.

Comments

  1. STD tests29 May 2012 at 00:34

    I like the way you describe these points here. Your post is very interesting, and I really enjoyed reading it

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more